삼성제약

001360KOSPI의약품 제조업

63.5 / 100

Reference Date: 2026-04-13

Financial Score23.0 / 40

News Sentiment17.5 / 25

Momentum13.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue is on a declining trend. Slightly down 3.7% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Samsung Pharmaceutical operates in pharmaceutical manufacturing and sales, biopharma, and health food sectors, distributing a wide range of products including specialty and over-the-counter drugs. The company is advancing clinical trials for pancreatic cancer treatment GV1001 and Alzheimer's disease, with revenue reaching 460.7 billion KRW in 2025.

Number of Employees

87people

Average Salary

66.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

14.69Industry Average 14.805.0Point

In line with industry avg

PBR

1.41Industry Average 1.042.5Point

Higher than industry avg (caution)

ROE

10.18Industry Average 4.427.0Point

2.3x industry avg (excellent)

Debt Ratio

3.37Industry Average 11.988.0Point

Half of industry avg (excellent)

Trend 2023~20250.5 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼5.4% (2-year basis)

Operating Profit Growth Rate

0.5 / 3

Avg ▼2.0% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -10.9% (improving, 3yr)

Detailed News Sentiment

6 totalPositive 6Neutral 0Negative 0Average Sentiment Score 70

Positive
삼성제약 "진행성핵상마비 치료제 임상 환자 2년 장기 투약 중"
삼성제약은 진행성핵상마비(PSP) 치료제 'GV1001'의 임상시험에 참여했던 환자들이 식품의약품안전처 치료목적 사용승인 제도를 통해 추가 투약을 안정적으로 이어가고 있다고 밝혔습니다.
Positive
삼성제약, PSP 치료제 GV1001 장기 투약 지속…환자 치료 기회...
삼성제약은 PSP 치료제 'GV1001' 임상시험 환자들이 식약처 치료목적 사용승인 제도를 통해 장기 투약을 지속하며 환자 치료 기회를 확대하고 있다고 전했습니다.
Positive
삼성제약, PSP 환자 대상 장기 투약 순항
삼성제약은 진행성핵상마비(PSP) 치료제 'GV1001'의 임상시험에 참여했던 환자들이 식품의약품안전처 치료목적 사용승인 제도를 통해 추가 투약을 안정적으로 이어가고 있다고 밝혔습니다.

Detailed Momentum

52-week position5.0Point

52w mid range (55%)

Current 1,807Won52-week high 2,18052-week low 1,343

1-month return2.0Point

1m -3.73% (slight drop)

Volume trend6.0Point

Volume increasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0

Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-26
Neutral정기주주총회결과2026-03-26
Neutral감사보고서제출2026-03-18
Neutral사업보고서 (2025.12)2026-03-18